Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

New study reports glofitamab is effective in diffuse large B-cell lymphoma

Dec 11, 2022

A new Roche study published in the New England Journal of Medicine reported that first in class bispecific (anti-CD20/anti-CD3) antibody glofitamab [CD20-TCB, also known as RG6026] is effective in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).  Australia’s Peter MacCallum Cancer Centre played a major role in this study, treating the first patients in the world with glofitamab.  Roche’s glofitamab is yet to be approved, but it has received orphan drug status in Australia and the EU for DLBCL.